TScan Therapeutics
liquid tumor program addresses a large and growing market | TScan Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
July 2021
Slide
21 of 43
Related slides by other companies
Genprex
Investor Presentation
November 2024
novel gene therapy diabetes program intends to address both and | Genprex
Erasca
Investor Presentation
November 2023
eras could address high unmet need in patients in us and | Erasca
Kymera
Investor Day
December 2021
degrader first in class opportunity to address driven pathology across diverse indications first degrader against an undrugged target in the clinic profound single agent activity in liquid tumor and promising activity with anti in liquid and solid tumors clinical development strategy includes direct registrational path in pathway activated heme malignancies opportunity for expansion into solid tumors in combination with immune inhibitors | Kymera
Ginkgo
Investor Conference
June 2021
we design when working on programs | Ginkgo
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights